Epigenetic dysregulation in autophagy signaling as a driver of viral manifested oral carcinogenesis

• Published in: Biochimica et biophysica acta. Molecular basis of disease 2022-11, Vol.1868 (11), p.166517-166517, Article 166517
• Main Authors: Patra, Srimanta, Patil, Shankargouda, Das, Surajit, Bhutia, Sujit Kumar
• Format: Article
• Language: English
• Subjects: Autophagy; Epi-drugs; Epigenetics; Oral cancer; Viral infection
• ISSN: 0925-4439; 1879-260X
• DOI: 10.1016/j.bbadis.2022.166517

Concurrent viral infections insist on dysregulated epigenetics of tumor suppressor genes (TSGs), cell cycle regulators, apoptosis, and autophagy-associated genes to manifest oral carcinogenesis. Autophagy has been projected as a strategic defense signaling cascade against viral entry and subsequent oral carcinogenesis. Compromised autophagy signaling during viral infection fuels oral cancer initiation and progression. The aberrant expression of autophagy genes and their encoded proteins is catalyzed by the dysregulated epigenome, legitimate epigenomic mutations, and post-transcriptional modifications such as hypermethylation, deacetylation of histone and non-histone targets, and hyperacetylation of histones that drive malignant transformation during oral carcinogenesis. Recent investigations have predicted epi-drugs (intriguingly methylation and deacetylation inhibitors and activators) as next-generation oral cancer therapeutic agents with a special notation for autophagy regulation. This review focuses on the epigenetic mediated post-transcriptional modulation of autophagy genes during viral manifested oral carcinogenesis with a distinctive perception of autophagy-modulating epi-drugs in oral cancer therapeutics. •Epigenetic dysregulation of candidate genes facilitate oral carcinogenesis.•Epigenetically dysregulated autophagy drives viral manifested oral carcinogenesis.•Autophagy modulating epi-drugs are the potent next generation chemotherapeutics.